We are a market leader with over 15 years of experience in the field of clinical proteomics.
While genomic data uncover the potential genetic drivers of cancer (tumor), proteomic data profile the patient’s (host) immune response to their cancer. Both are critical elements for interpreting the real-time complexity of the cancer disease state (cancer ecosystem).
Image adapted from Chen and Mellman 2016 for educational purposes.
We are experts at profiling the patient's immune response to their cancer with blood-based proteomic solutions in addition to traditional genomic insights. Our technologies and machine learning expertise allow us to identify clinically relevant proteomic differences in patient populations to help guide treatment strategy.
We have developed the DeepMALDI® system, a proprietary high-density matrix-assisted laser desorption/ionization time-of-flight (MALDI-ToF) mass spectrometry (MS) technology, to produce high-quality protein data content for the discovery of diagnostic tests with clinical utility.
We use LC-MS for both targeted and discovery proteomics as it offers highly sensitive, specific, and cost-effective analysis for simultaneous quantitation of hundreds to several thousands of targeted peptides in a single experiment.
We use ELISA to detect and quantify the presence of antibodies and proteins in patient blood samples by exploiting the interaction between antigen and antibody.